GH Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Guardant Health (NASDAQ: GH)
›
Guardant Health (NASDAQ: GH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 2,490 employees.
The shares were at 145.83 USD on 20 November 2026, up 50.8% over 52 weeks. Its 52-week range is 74.55 USD to 191.01 USD: the price is 23.7% below the high and 95.6% above the low.
Its market capitalisation is 19.73B USD.
Guardant Health reports return on equity of 419.2%, an operating margin of -39.4% and revenue up 36.1% year over year.
Its debt exceeds its cash by 664.59M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 25 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 200.76 USD is 37.7% above the current price. The next earnings report is expected on 18 February 2027.